Mark K Hvistendahl Selected Research

apraglutide

1/2022	Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.
1/2022	Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark K Hvistendahl Research Topics

Disease

3	Short Bowel Syndrome 05/2022 - 01/2022
2	Intestinal Failure 01/2022 - 01/2022

Drug/Important Bio-Agent (IBA)

3	Glucagon (Glukagon)FDA Link 05/2022 - 01/2022
2	apraglutideIBA 01/2022 - 01/2022

Therapy/Procedure

1	Subcutaneous Injections 05/2022